克唑替尼可克服对CH5424802的获得性耐药：MET基因扩增是关键因素吗？ - Suppr

Suppr

超能文献

Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?

作者信息

Gouji Toyokawa, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose

机构信息

Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan.

出版信息

J Thorac Oncol. 2014 Mar;9(3):e27-8. doi: 10.1097/JTO.0000000000000113.

DOI:10.1097/JTO.0000000000000113

PMID:24518097

Abstract

摘要

相似文献

Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?

J Thorac Oncol. 2014 Mar;9(3):e27-8. doi: 10.1097/JTO.0000000000000113.

Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation.

J Thorac Oncol. 2013 Nov;8(11):e96-8. doi: 10.1097/JTO.0b013e3182a008ed.

Complete response to crizotinib in a patient with adenocarcinoma of the lung cancer harboring c- MET amplification.

J BUON. 2017 Jan-Feb;22(1):279-280.

Crizotinib in the management of advanced-stage non-small-cell lung cancer.

Future Oncol. 2015;11(5):735-45. doi: 10.2217/fon.14.314.

Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.

Oncotarget. 2017 Apr 18;8(16):26281-26287. doi: 10.18632/oncotarget.15457.

Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.

J Thorac Oncol. 2013 Dec;8(12):e105-6. doi: 10.1097/JTO.0b013e3182a00e37.

[Interest of crizotinib in a lung cancer patient with de novo amplification of MET].

Rev Mal Respir. 2017 Jan;34(1):57-60. doi: 10.1016/j.rmr.2016.05.007. Epub 2016 Oct 13.

Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.

Int J Oncol. 2015 Mar;46(3):1025-30. doi: 10.3892/ijo.2014.2797. Epub 2014 Dec 15.

High-dose crizotinib for brain metastases refractory to standard-dose crizotinib.

J Thorac Oncol. 2013 Sep;8(9):e85-6. doi: 10.1097/JTO.0b013e31829cebbb.

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.

J Thorac Oncol. 2019 Jul;14(7):e137-e139. doi: 10.1016/j.jtho.2019.04.021. Epub 2019 May 2.

引用本文的文献

Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.

Front Immunol. 2024 Apr 9;15:1366260. doi: 10.3389/fimmu.2024.1366260. eCollection 2024.

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?

Curr Oncol. 2023 May 16;30(5):5072-5092. doi: 10.3390/curroncol30050384.

Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review.

Transl Lung Cancer Res. 2023 Mar 31;12(3):615-628. doi: 10.21037/tlcr-22-708. Epub 2023 Mar 20.

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis.

Clin Cancer Res. 2023 May 15;29(10):1879-1886. doi: 10.1158/1078-0432.CCR-22-3318.

Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene.

Intern Med. 2023 Nov 1;62(21):3215-3221. doi: 10.2169/internalmedicine.1164-22. Epub 2023 Mar 15.

Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis.

Int J Mol Sci. 2023 Jan 23;24(3):2242. doi: 10.3390/ijms24032242.

MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities.

Cancers (Basel). 2023 Jan 18;15(3):612. doi: 10.3390/cancers15030612.

Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.

Mol Biomed. 2022 Dec 12;3(1):42. doi: 10.1186/s43556-022-00107-x.

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2/3-Generation ALK Tyrosine Kinase Inhibitors (TKIs).

Front Oncol. 2022 May 13;12:874712. doi: 10.3389/fonc.2022.874712. eCollection 2022.

Complex genetic alterations contribute to rapid disease progression in an rearrangement lung adenocarcinoma patient: a case report.

Transl Cancer Res. 2021 Jun;10(6):3081-3086. doi: 10.21037/tcr-20-3473.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验